Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 149

Sort by

Sort Order Select

Journal Articles

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Blood (2024) 143 (23): 2363–2372.

https://doi.org/10.1182/blood.2023023502

Published: 2024

Includes: Supplemental data

Journal Articles

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy

Côme Bommier, Emanuele Zucca, Sylvie Chevret, Annarita Conconi, Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Catherine Thieblemont, Jérôme Lambert

Blood (2024) 143 (5): 422–428.

https://doi.org/10.1182/blood.2023020984

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Tolerance of the BNT162b2 Vaccine in Children with Acute Leukemia and Their Siblings: Results of the Phase I-II Pacific Trial

Fanny Alby Laurent, Amani Ouedrani, Pierre Jatteau, Marion Strullu, Claire Montlahuc, Chaima Mrad, Audrey Guilmatre, Maxime Ferreboeuf, Anne-France Ray-Lunven, Florentia Kaguelidou, Lucienne Chatenoud, Laurence Morand-Joubert, Sylvie Chevret, Arnaud Petit

Blood (2023) 142 (Supplement 1): 4246.

https://doi.org/10.1182/blood-2023-181899

Published: 2023

Journal Articles

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Marie Anne Hospital, Thomas Cluzeau, Alice Garnier, Giovanni Marconi, Emmanuelle Tavernier, Sylvain Thepot, Aspasia Stamatoullas, Cristina Papayannidis, Sophie Park, Noemie Bigot, Lamya AIT SI Selmi, Fatiha Chermat, Sylvie Chevret, Pierre Fenaux

Blood (2023) 142 (Supplement 1): 2923.

https://doi.org/10.1182/blood-2023-185609

Published: 2023

Journal Articles

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

Jean-Jacques Kiladjian, Jean-Christophe Ianotto, Juliette Soret, Nabih Maslah, Cendrine Chaffaut, Françoise Boyer perrard, Fiorenza Barraco, Viviane Dubruille, Claude Capron, Amandine Tisserand, Valérie Rolland-Neyret, Zineb Ghrieb, Sylvie Chevret, Isabelle Plo, Marie-Hélène Schlageter, Veronique Meignin, Matthieu Resche-Rigon, Bruno Cassinat

Blood (2022) 140 (Supplement 1): 577–578.

https://doi.org/10.1182/blood-2022-156389

Published: 2022

Journal Articles

CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM

Pierre Peterlin, Pascal Turlure, Patrice Chevallier, Marie-Pierre Gourin, Pierre-Yves Dumas, Sylvain Thepot, Anna Berceanu, Sophie Park, Marie Anne Hospital, Thomas Cluzeau, Jose Miguel Torregrosa Diaz, Louis Devron, Sylvie Chevret, Marie C Bene, Yannick Le Bris, Rosa Sapena, Fatiha Chermat, Sophie Dimicoli-Salazar, Pierre Fenaux

Blood (2021) 138 (Supplement 1): 243.

https://doi.org/10.1182/blood-2021-145123

Published: 2021

Journal Articles

Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

Blood (2021) 138 (Supplement 1): 876.

https://doi.org/10.1182/blood-2021-145184

Published: 2021

Journal Articles

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Blood (2021) 138 (Supplement 1): 512.

https://doi.org/10.1182/blood-2021-148843

Published: 2021

Journal Articles

Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial

Blood (2021) 138 (Supplement 1): 3478.

https://doi.org/10.1182/blood-2021-150126

Published: 2021

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Blood (2021) 138 (Supplement 1): 1842.

https://doi.org/10.1182/blood-2021-146846

Published: 2021

Journal Articles

Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients

Sara Villar, Sylvie Chevret, Xavier Poire, Amandine Charbonnier, Patrice Chevallier, Jean-Henri Bourhis, Edouard Forcade, Sylvain Chantepie, David Beauvais, Nicole Raus, Jacques-Olivier Bay, Michael Loschi, Raynier Devillier, Remy Duléry, Patrice Ceballos, Marie Thérèse Rubio, Yves Beguin, Stephanie Nguyen, Marie Robin

Blood (2021) 138 (Supplement 1): 1844.

https://doi.org/10.1182/blood-2021-146380

Published: 2021

Journal Articles

Comparison of Characteristics and Laboratory Tests of COVID 19-Hematological Patients from France and Brazil: Identification of Prognostic Driven Profiles

Lucas Bassolli de Oliveira Alves, Lilith Faucheux, Giancarlo Fatobene, Sylvie Chevret, Vanderson Rocha

Blood (2021) 138 (Supplement 1): 4070.

https://doi.org/10.1182/blood-2021-152649

Published: 2021

Journal Articles

Clonal Hematopoiesis Driven By MDM4 Amplification Defines a Canonical Route Towards Secondary MDS/AML in Fanconi Anemia Patients

Blood (2021) 138 (Supplement 1): 860.

https://doi.org/10.1182/blood-2021-147811

Published: 2021

Journal Articles

Lenalidomide Exposure at Time of CAR T-Cells Expansion Enhances Response of Refractory/Relapsed Aggressive Large B-Cell Lymphomas

Jean Lemoine, Florence Morin, Roberta Di Blasi, Laetitia Vercellino, Alexis Cuffel, Naoufal Benlachgar, Jerome Larghero, Isabelle Madelaine, Julien Calvani, Veronique Meignin, Sophie Caillat-Zucman, Sylvie Chevret, Catherine Thieblemont

Blood (2021) 138 (Supplement 1): 1433.

https://doi.org/10.1182/blood-2021-151109

Published: 2021

Journal Articles

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 62.

https://doi.org/10.1182/blood-2021-146932

Published: 2021

Journal Articles

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

Blood (2021) 138 (Supplement 1): 63.

https://doi.org/10.1182/blood-2021-147898

Published: 2021

Journal Articles

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

Blood (2021) 138 (Supplement 1): 3697.

https://doi.org/10.1182/blood-2021-150904

Published: 2021

Journal Articles

A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

Blood (2021) 137 (4): 524–532.

https://doi.org/10.1182/blood.2020005524

Published: 2021

Includes: Supplemental data

Journal Articles

Impact of Two Different Types of Rabbit ATG on Immune Reconstitution and Overall Results after Allogeneic Hematopoetic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Children

Camille Feltesse, Karima Yakouben, MD, Mony Fahd, MDMSc, Marie Ouachee, MD, Lou le Mouel, MDMSc, Jérôme Le Goff, PharmD, PhD, Guislaine Carcelain, MD PhD, Valérie Guérin, MD MSc, André Baruchel, MD, Sylvie Chevret, MD PhD, Jean-Hugues Dalle, MD PhD

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-142374

Published: 2020

Journal Articles

Lenalidomide Enhance CAR T-Cells Response in Patients with Refractory/Relapsed Large B Cell Lymphoma Experiencing Progression after Infusion

Catherine Thieblemont, MD PhD, Sylvie Chevret, MD PhD, Vincent Allain, Roberta Di Blasi, Florence Morin, Laetitia Vercellino, Sandrine Roulland, PhD, Karin Tarte, PhDPharmD, Veronique Meignin, Sophie Caillat-Zucman, MD PhD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-136279

Published: 2020

NARROW

Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy

Efficacy and Tolerance of the BNT162b2 Vaccine in Children with Acute Leukemia and Their Siblings: Results of the Phase I-II Pacific Trial

A Phase II Study of Single Agent Aspacytarabine (BST-236) in Adults Unfit for Intensive Chemotherapy with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) or Higher Risk Myelodysplastic Syndromes (R/R HR MDS)

Final Results of Ruxopeg, a Phase 1/2 Adaptive Randomized Trial of Ruxolitinib (Rux) and Pegylated Interferon Alpha (IFNa) 2a in Patients with Myelofibrosis (MF)

CPX 351 As First Line Treatment in Higher Risk MDS. a Phase II Trial By the GFM

Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial

Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT) in Patients with IPSS Low or Intermediate-1 Myelodysplastic Syndrome (MDS): A Prospective Multicenter Phase II Study Based on Donor Availability By the GFM & SFGM-TC "MDS-ALLO-Risk"

Impact of Pre-Graft Ruxolitinib on Post-Transplantation Outcome in Myelofibrosis Patients

Comparison of Characteristics and Laboratory Tests of COVID 19-Hematological Patients from France and Brazil: Identification of Prognostic Driven Profiles

Clonal Hematopoiesis Driven By MDM4 Amplification Defines a Canonical Route Towards Secondary MDS/AML in Fanconi Anemia Patients

Lenalidomide Exposure at Time of CAR T-Cells Expansion Enhances Response of Refractory/Relapsed Aggressive Large B-Cell Lymphomas

Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group

Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group

A Phase II Study of the Efficacy and Tolerance of Azacytidine (AZA) in Steroid Dependent/Refractory Systemic Autoimmune and Inflammatory Disorders (SAID) Associated with MDS or CMML (GFM- AZA-SAID -trial)

A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

Impact of Two Different Types of Rabbit ATG on Immune Reconstitution and Overall Results after Allogeneic Hematopoetic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in Children

Lenalidomide Enhance CAR T-Cells Response in Patients with Refractory/Relapsed Large B Cell Lymphoma Experiencing Progression after Infusion

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only